VEA
Virtus ETF Advisers Portfolio holdings
AUM
$75.7M
1-Year Return
23.01%
This Quarter Return
-1.04%
1 Year Return
+23.01%
3 Year Return
+79.79%
5 Year Return
+153.94%
10 Year Return
–
AUM
$165M
AUM Growth
-$4.08M
(-2.4%)
Cap. Flow
+$1.01M
Cap. Flow
% of AUM
0.61%
Top 10 Holdings %
Top 10 Hldgs %
6.09%
Holding
488
New
53
Increased
73
Reduced
307
Closed
54
Top Buys
| 1 |
Halliburton
HAL
|
$819K |
| 2 |
Alphabet (Google) Class A
GOOGL
|
$814K |
| 3 |
Steel Dynamics
STLD
|
$798K |
| 4 |
Caterpillar
CAT
|
$792K |
| 5 |
Booking.com
BKNG
|
$789K |
Top Sells
| 1 |
Netflix
NFLX
|
$1.05M |
| 2 |
Vulcan Materials
VMC
|
$1.01M |
| 3 |
CoStar Group
CSGP
|
$998K |
| 4 |
Eli Lilly
LLY
|
$967K |
| 5 |
Ingersoll Rand
IR
|
$913K |
Sector Composition
| 1 | Healthcare | 18.63% |
| 2 | Financials | 17.26% |
| 3 | Technology | 14.89% |
| 4 | Energy | 9.42% |
| 5 | Consumer Discretionary | 8.66% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
376
Atea Pharmaceuticals
AVIR
$267M
| $72.5K | 0.04% |
24,183
-2,403
| -9% | -$7.21K |
|
377
Celldex Therapeutics
CLDX
$1.52B
| $72.4K | 0.04% |
2,631
-261
| -9% | -$7.18K |
|
378
Replimune Group
REPL
$494M
| $72.1K | 0.04% |
4,216
-415
| -9% | -$7.1K |
|
379
Erasca
ERAS
$457M
| $71.9K | 0.04% |
36,494
-3,631
| -9% | -$7.15K |
|
380
ATAI Life Sciences
ATAI
$980M
| $71.7K | 0.04% |
55,554
-5,535
| -9% | -$7.14K |
|
381
Dyne Therapeutics
DYN
$2.02B
| $71.4K | 0.04% |
7,972
-797
| -9% | -$7.14K |
|
382
89bio
ETNB
$1.32B
| $71.3K | 0.04% |
4,619
-465
| -9% | -$7.18K |
|
383
Nurix Therapeutics
NRIX
$758M
| $70.8K | 0.04% |
9,011
-901
| -9% | -$7.08K |
|
384
Pliant Therapeutics
PLRX
$114M
| $70.5K | 0.04% |
4,066
-403
| -9% | -$6.99K |
|
|
KRTX
385
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $70K | 0.04% |
414
-39
| -9% | -$6.59K |
|
386
Relay Therapeutics
RLAY
$710M
| $69.6K | 0.04% |
8,272
-820
| -9% | -$6.9K |
|
387
Editas Medicine
EDIT
$248M
| $69.5K | 0.04% |
8,914
-891
| -9% | -$6.95K |
|
388
Intellia Therapeutics
NTLA
$1.29B
| $69.3K | 0.04% |
2,192
-214
| -9% | -$6.77K |
|
389
Geron
GERN
$893M
| $67.9K | 0.04% |
32,005
-3,185
| -9% | -$6.75K |
|
|
INBX
390
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $67.5K | 0.04% |
3,678
-366
| -9% | -$6.72K |
|
391
CureVac
CVAC
$1.21B
| $66.4K | 0.04% |
9,723
-969
| -9% | -$6.62K |
|
|
PNT
392
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
| $66.4K | 0.04% |
9,954
-985
| -9% | -$6.57K |
|
393
Prothena Corp
PRTA
$460M
| $66.2K | 0.04% |
1,372
-141
| -9% | -$6.8K |
|
394
Arvinas
ARVN
$575M
| $66K | 0.04% |
3,361
-338
| -9% | -$6.64K |
|
395
Syndax Pharmaceuticals
SNDX
$1.47B
| $65.8K | 0.04% |
4,532
-451
| -9% | -$6.55K |
|
396
Cassava Sciences
SAVA
$104M
| $65K | 0.04% |
3,907
-386
| -9% | -$6.42K |
|
|
EXAI
397
DELISTED
Exscientia Plc American Depositary Shares
EXAI
| $64.4K | 0.04% |
14,247
-1,421
| -9% | -$6.42K |
|
|
CERE
398
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| $63.2K | 0.04% |
2,895
-287
| -9% | -$6.27K |
|
399
Aldeyra Therapeutics
ALDX
$334M
| $63.2K | 0.04% |
9,460
-941
| -9% | -$6.29K |
|
400
Allogene Therapeutics
ALLO
$255M
| $62.9K | 0.04% |
19,835
-1,978
| -9% | -$6.27K |
|